Difference between revisions of "Lusutrombopag (Mulpleta)"
Jump to navigation
Jump to search
m |
m |
||
| Line 7: | Line 7: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 2018-07-31: Approved for [[Thrombocytopenia in liver disease|thrombocytopenia in adults with chronic liver disease]] who are scheduled to undergo a medical or dental procedure. | * 2018-07-31: Approved for [[Thrombocytopenia in liver disease|thrombocytopenia in adults with chronic liver disease]] who are scheduled to undergo a medical or dental procedure. | ||
| − | + | ==History of changes in PMDA indication== | |
| + | *2015-09-28: New approval for the improvement of [[Thrombocytopenia in liver disease|thrombocytopenia in patients with chronic liver disease]] for whom an elective invasive procedure is planned. | ||
==Also known as== | ==Also known as== | ||
*'''Brand name:''' Mulpleo, Mulpleta | *'''Brand name:''' Mulpleo, Mulpleta | ||
| Line 20: | Line 21: | ||
[[Category:FDA approved in 2018]] | [[Category:FDA approved in 2018]] | ||
| + | [[Category:PMDA approved in 2015]] | ||
Latest revision as of 19:14, 9 June 2023
Mechanism of action
Thrombopoietin receptor agonist
Diseases for which it is used
History of changes in FDA indication
- 2018-07-31: Approved for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.
History of changes in PMDA indication
- 2015-09-28: New approval for the improvement of thrombocytopenia in patients with chronic liver disease for whom an elective invasive procedure is planned.
Also known as
- Brand name: Mulpleo, Mulpleta